Genome-proteome system for prostate cancer by Maxim N Peshkov
MEETING ABSTRACT Open Access
Genome-proteome system for prostate cancer
Maxim N. Peshkov
From EPMA-World Congress 2013
Brussels, Belgium. 20-21 September 2013
Cancer of prostate is challenging medical issue which pre-
valence ranking in men among all oncologic diseases cor-
responds to the 4th most prevalent in Russia, 2nd-3rd in
West Europe and 1st in USA since year 2007. The most
promising approach follows the strategy of early detection
of tumor progress prior to clinical manifestation in pros-
tate gland. The PSA (prostate specific antigen) is used as
the universal marker in clinical practice since 1979 year,
however, with modest success. Hence, 40% of prostate
cancer patients demonstrate normal levels of PSA
(n<2,5ng/ml), and only 60% of the patients have higher
levels of PSA (n>4,0 ng/ml). Consequently, the world
research community further efforts to develop more speci-
fic and sensitive markers for early detection of pre-cancer-
ous lesions in prostate gland. A promising tool might be
“omics” and in particular “proteomics” technologies. Pre-
dictive, Preventive and Personalized medicine is consid-
ered as the medicine of XXI century with following
requirements: risk assessment, disease specific profiles,
early/predictive diagnostics, disease/treatment monitoring,
reliable prognosis, and treatments tailored to the person.
Scientific objectives
development of a genomic-proteomic system for early
diagnosis and clinical monitoring of patients with pros-
tate cancer as follows:
• To determine a genome-wide significant association
between PSA level and single-nucleotide polymorphisms
(SNPs) at loci;
• To define potential candidates for blood peptide’s
biomarker expression database, as the platform for the
identification, quantification and validation of protein
biomarker(s) during prostate cancer progression;
• To create a centralized prostate cancer urine pep-
tide’s biomarker expression database with add value for
the blood biomarkers database;
• To analyze diagnostic accuracy of the prostate can-
cer biomarker candidates;
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Table 1 Types of prostate cancer specific alterations that can be potentially considered as biomarker candidates
Level of research Research unit Biomaterial Detection technology




Transcriptome MicroRNAs (miRNAs) Blood MALDI-TOF based mini-sequencing
Reduced mRNA editing Blood Reverse-Transcriptase-PCR
Proteome Protein of plasma Blood plasma Multiple Reaction Monitoring, (MRM)





Multiple Reaction Monitoring, (MRM) and Information
Dependent Acquisition (IDA)
Metabilites Protein of plasma Blood plasma Multiple Reaction Monitoring, (MRM)
Protein of urine Urine Multiple Reaction Monitoring, (MRM)
Macro-micro tissue analysis
(morphological diagnosis)
Tissue Biopsy material Microscopy, immunohistochemistry
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• To create innovative approaches for risk assessment,
therapy monitoring and treatment management for this
patient cohort.
Methodology
With altogether over 1000 prostate cancer patients a
robust database has been created in the study for follow-
up molecular biological analysis. To estimate a genome-
wide significant association between PSA level and single-
nucleotide polymorphisms (SNPs) at loci, MALDI-TOF
based mini-sequencing of blood samples is utilized.
Outlook
The sequencing data will be correlated with other para-
meters such as individual PSA levels, cancer stage and
tumor aggressiveness. In the next steps, blood and urine
profiles will be analyzed at the level of proteins. Multi-
factorial analyses are expected to reveal correlated
between individual parameters. Creation of the genome-
transcriptome-proteome patterns is the promising
approach to establish early detection, predictive diagnos-
tics, reliable prognostics and improved management of
prostate cancer.
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